PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
16.61%
Net income growth 15-20% – Very strong. Benjamin Graham would check if leverage or cyclical factors boost earnings artificially.
4.17%
D&A up to 5% yoy – Manageable. Seth Klarman would see normal expansions if revenue justifies the extra depreciation.
-100.00%
A negative yoy change in deferred tax might cut future liabilities. Benjamin Graham would verify whether real tax payments are simply being recognized sooner.
-2.08%
Negative yoy SBC growth reduces new equity issuance. Benjamin Graham would verify that enough talent investment remains for growth.
-115.45%
A negative yoy change in working capital can free up cash. Benjamin Graham would confirm it is not from falling demand or asset disposal.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.13%
A negative yoy AP change means the firm is paying down supplier credit. Benjamin Graham would see it as lowering short-term liabilities if revenue is stable.
-68.80%
A negative yoy shift in other WC might free up cash flow. Benjamin Graham would confirm the items are not essential to operations or revenue generation.
119.47%
Above 30% yoy – Major jump. Philip Fisher would investigate whether this is a recurring or truly one-time distortion.
9.84%
Operating cash flow growth 5-10% – Moderate. Peter Lynch would hope expansions can further boost core cash generation.
98.37%
CapEx above 15% yoy – Significant. Philip Fisher would demand strong evidence of high-ROI projects to offset the spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.37%
Above 15% yoy – Heavy. Philip Fisher would require evidence these invests drive future returns and do not hamper free cash flow too much.
64.41%
Debt repayment growth above 20% yoy – Strong deleveraging. Warren Buffett would see improved balance sheet health unless expansions are starved.
-34.38%
A negative yoy figure could mean fewer or no new shares or even net buybacks. Benjamin Graham would see it as positive unless expansions need capital that internal cash cannot provide.
No Data
No Data available this quarter, please select a different quarter.